Baseline Epiproteomics Reveals Proteoform-Level Separation Between TNF Inhibitor Responders and Non-Responders in Rheumatoid Arthritis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #1039; Pres time: Nov 9, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; " Peripheral blood mononuclear cell samples from 49 RA patients with moderate-to-high disease activity prior to initiation of TNF inhibitors (adalimumab, etanercept, infliximab, or certolizumab pegol) were analyzed according to the workflow in Fig. Baseline epiproteomic profiling reveals proteoform- and PTM-level differences between responders and non-responders to TNF inhibitors in RA. Integration of PTM and proteoform information enhances molecular resolution beyond protein-level approaches and supports improved utility for distinguishing responder status at baseline. The identified features suggest that differential balance between inflammatory amplification and regulatory control pathways may underlie baseline immune states associated with TNF inhibitor response."
Immune Modulation • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • Targeted Protein Degradation • PIAS4 • USP5
|
|
Aaron Javitt1; Noa Molshatzki2; Reut Yosef3; Adi Silberman4; Yuval Butnik5; Dayana Yahalomi6; Assaf Kacen7; Dana Ascherman8
|